Latest Platform Growth News

Streamplay Studio Limited reports its second consecutive cash-flow positive quarter, driven by strong game launches and platform growth across Tier 1 markets and emerging regions.

Spectur Limited reported a strategic revenue shift in Q1 FY26, with SaaS recurring revenue growing 5% year-on-year despite an overall 9% quarterly revenue dip. The company also raised $2.3 million to accelerate its solar-powered AI platform development.

Rhythm Biosciences reports strong Q1 FY26 progress, securing strategic partnerships and advancing commercial readiness for its ColoSTAT® colorectal cancer test alongside robust growth in its geneType platform.

MA Financial Group has reported a surge in assets under management and loan book growth alongside a major $525 million property acquisition, signaling robust momentum across its financial services divisions.

Praemium reported a robust start to FY2026 with total Funds Under Administration rising 13% to $67 billion, led by strong organic growth in its Spectrum platform. The company’s strategic focus on high-net-worth clients and platform consolidation continues to gain traction.

HUB24 has reported a record $5.2 billion in net inflows for Q1 FY26, boosting its Funds Under Administration to $146.5 billion and securing the top spot for adviser satisfaction in Australia.

Aspermont Limited has completed its Share Purchase Plan and shortfall placement, raising over A$1 million to fund its digital transformation and AI-driven services expansion.

Hiremii Group has successfully raised $650,000 through an oversubscribed placement, underscoring strong investor confidence as it pushes forward with commercialising its AI-driven recruitment platform.

SiteMinder's 2025 Investor Day presentation highlights its Smart Platform's progress, AI-driven hotel revenue tools, and reiterates a strong FY26 outlook with ambitions for accelerated growth.

Aspermont Limited has raised an additional $891,210 through its Share Purchase Plan, complementing a recent $1.75 million institutional placement. This capital injection supports the company’s strategic pivot towards data-driven mining intelligence and AI-powered services.

Osteopore Limited has established OsteoRx, a new special purpose vehicle, with an initial AUD 0.5 million investment to accelerate breakthroughs in cellular regenerative medicine. This strategic move integrates a controlling stake in US-based RxCell Inc, expanding Osteopore’s footprint in the fast-growing stem cell market.

Butn Limited has reported record revenue growth and its first positive operating cash flow for FY25, alongside securing a substantial $100 million funding facility to fuel future expansion.